Infusion centers sell for 3.5x to 6.5x Seller's Discretionary Earnings (SDE), measuring the owner's net benefit including owner compensation, owner benefits, and normalized operating profit, or 6.0x to 11.0x EBITDA, measuring earnings before interest, taxes, depreciation, and amortization from patient infusion visits and specialty drug administration. Centers with growing patient volumes, high-value specialty drug mixes, diversified payer contracts, multiple physician referral sources, and accreditation credentials consistently achieve the upper range. The valuation spread reflects patient volume growth, drug mix quality, payer relationship strength, and compliance credentials that buyers evaluate when pricing infusion center acquisitions.

Patient visit volume and growth trajectory demonstrate market demand and operational scalability. Centers managing 50-150 patient visits weekly generate $200,000-600,000 annual revenue per treatment chair depending on drug mix composition and reimbursement rates. Visit volume growth of 15%+ annually indicates expanding market penetration and physician referral momentum. Centers with stable or declining visit counts face reimbursement pressure and operational efficiency challenges that reduce multiples. Buyer platforms integrate acquired centers into existing provider networks and clinical relationships, so demonstrated growth indicates acquisition value within larger platform strategies and network economics.

Drug mix composition drives reimbursement rates and gross profitability. High-value specialty drugs including monoclonal antibodies, biologics, and immunosuppressive therapies generate $1,500-3,500 per infusion session and 40-50% gross margins after drug costs and clinical labor. Commodity infusions generate $400-800 per session with 20-30% margins. Centers with 60%+ specialty drug composition outperform commodity-focused operations significantly. Specialty drug protocols require advanced clinical expertise, extended treatment protocols, and higher drug inventory investment. Payer contracts and physician ordering patterns drive drug mix evolution. Buyers model drug mix sustainability based on referral physician specialty mix and market trends.

Payer contract diversity eliminates reimbursement concentration risk and supports consistent volume growth. Centers with in-network agreements across Medicare, Medicaid, Blue Shield, UnitedHealth, Aetna, and regional carriers demonstrate established payer relationships and credentialing infrastructure. Single-payer dependent operations face existential risk if the payer terminates contracts, reduces rates, or shifts volume to competitors. Contract terms including reimbursement per infusion, specialty drug markup allowances, and contract duration vary significantly by payer and competitive landscape. Buyer platforms with existing payer relationships can credentially acquired centers faster, reducing integration timeline and acceleration risk. Similar network integration strategies apply to our medical practice business valuation analysis, where payer relationships anchor valuation.

Physician referral diversity across multiple specialties provides volume stability and market penetration breadth. Centers with 30-plus active referring physicians across oncology, rheumatology, immunology, and gastroenterology reduce single-provider dependency and concentration risk. High concentration from fewer than 10 physicians creates vulnerability if key physicians retire, relocate, or shift referrals to competing centers. Physician relationships reflect clinical quality reputation, treatment scheduling efficiency, and patient satisfaction metrics. Buyer networks leverage existing provider relationships to expand referral reach for acquired centers.

ACHC or URAC accreditation demonstrates clinical quality compliance and operational governance, qualifying centers for expanded payer contracts and premium reimbursement rates. Accreditation requires documented clinical protocols, staff training programs, outcome tracking systems, and periodic external audits. Accredited centers access contracts and rates unavailable to non-accredited competitors. Accreditation investment of $10,000-25,000 annually generates multiple basis points of reimbursement premium and payer relationship expansion opportunities. Non-accredited centers face payer contract limitations that reduce valuation multiples.

Chair utilization rates measuring treatment time as percentage of operating capacity determine revenue potential and expansion needs. Centers with 75%+ utilization maximize revenue per installed chair and operational efficiency. Under-utilized facilities possess growth potential without infrastructure investment. Over-utilized centers may require expanded hours or additional treatment chairs at $30,000-80,000 per chair depending on infusion pump systems and monitoring equipment. Buyer platforms optimize capacity deployment across multi-center networks.

Adjusted EBITDA normalizes owner compensation, discretionary expenses, and non-recurring items to establish comparable earnings. An infusion center generating $1.2M annual revenue with $300,000 adjusted EBITDA at 8.0x values at $2.4M enterprise value. A comparable center with growing visit volumes, high specialty drug mix, and diversified payers might command 10.0x, or $3.0M—the $600,000 premium reflects volume growth momentum and payer security. Centers with flat visit volumes and commodity drug mixes trade at 4.0x-5.5x multiples.

The buyer landscape includes healthcare platform PE firms at 9.0x-11.0x EBITDA rolling up regional centers into large networks, established medical practices at 6.0x-8.0x expanding infusion revenue lines, hospital and health system networks at 7.0x-9.0x integrating outpatient infusion, and independent oncology practices at 5.0x-7.0x diversifying revenue streams. PE platforms pay top multiples because acquired centers benefit from centralized purchasing of specialty drugs, consolidated clinical protocols, expanded payer relationships, and multi-center referral networks. Healthcare platforms reference our pharmacy business valuation framework for comparable drug-related service acquisition benchmarks. Related industries that follow similar consolidation dynamics include Home Healthcare.